“…The chemokine receptor CXCR3 is mainly activated by γ-inducible chemokines CXCL11, CXCL10, and CXCL9, directing activated T cells to the sites of inflammation, and is implicated to play a role in a myriad of inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, cancer, atherosclerosis, and allograft rejection; thus, CXCR3 is viewed as a promising drug target. − 8-Azaquinazolinone derivatives ( 169 – 173 ) were characterized as promising allosteric modulators of the chemokine receptor CXCR3 and commonly demonstrate properties of signaling bias and probe-dependence . Among them, 172 can inhibit CXC chemokine 11 (CXCL11)-dependent G protein activation over β-arrestin recruitment with 187-fold selectivity, and it inhibits CXCL11- over CXCL10-mediated G protein activation with 12-fold selectivity …”